Clinical trials: JIA
Endocrine System Diseases
Prevention of Growth Retardation by Early Treatment With Growth Hormone (GH) in Children With CJA Treated by Corticosteroid Therapy
To evaluate the effect of increasing the growth hormone dose on the statural response To assess the value of early treatment during the course of arthritic disease by comparing the height acquired in the medium term by children…
- Trial name
- NCT00174291
- Testing
- Somatropin
- Where
- France
- Volunteers
- 21 people
- Sponsor
- Pfizer
Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis
An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)
Optional open label, roll over extension study to investigate the efficacy and safety of secukinumab treatment in Juvenile Idiopathic Arthritis (JIA) subtypes of Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related…
- Trial name
- NCT03769168
- Testing
- Secukinumab
- Where
- 23 sites in United States, Belgium and 7 more
- Volunteers
- 55 people
- Sponsor
- Novartis Pharmaceuticals
Juvenile Idiopathic Arthritis Associated Uveitis
Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Uveitis
The investigators are doing this research study to see if tocilizumab (Actemra) is safe and effective when used for severe or refractory non-infectious uveitis.
- Trial name
- NCT01603355
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Eric B. Suhler
Juvenile Idiopathic Arthritis (JIA)
Short-Term Effects of Intra-Articular Corticosteroid Injection on Knee Function in Juvenile Idiopathic Arthritis
The purpose of this study is to evaluate the short-term clinical effects of intra-articular corticosteroid injections on knee joint functions in children and adolescents diagnosed with Juvenile Idiopathic Arthritis (JIA).
- Trial name
- NCT07709026
- Testing
- Intra-articular Corticosteroid Injection
- Where
- Turkey (Türkiye)
- Volunteers
- 17 people
- Sponsor
- Necmettin Erbakan University
Juvenile Dermatomyositis (JDM), Polyarticular Juvenile Idiopathic Arthritis
Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases
This is an investigator-initiated trial to evaluate the efficacy and safety of BCMA/CD70-targeted CAR-T in the treatment of refractory pediatric rheumatic diseases.
- Conditions
- Juvenile Dermatomyositis (JDM), Polyarticular Juvenile Idiopathic Arthritis, Systemic Sclerosis (SSc), Primary Sjogren's Syndrome
- Trial name
- NCT07184450
- Testing
- BCMA/CD70-targetd CAR-T
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Juvenile Chronic Arthritis
Juvenile Rheumatoid Arthritis
The purpose of this study is to determine the safety of anakinra in patients with Polyarticular-Course Juvenile Rheumatoid Arthritis, a form of rheumatoid arthritis affecting children.
- Trial name
- NCT00037648
- Testing
- Anakinra
- Volunteers
- 86 people
- Sponsor
- Amgen
Juvenile Dermatomyositis, Rheumatic Diseases
Comparison Of The Effects Of Two Different Exercise Training Based On Internal And External Focus In Children and Adolescents With Rheumatic Diseases
The study aims to compare the effects of two different exercise programs, based on distinct focus strategies, on physical fitness and fatigue in children and adolescents with rheumatic diseases.
- Conditions
- Juvenile Dermatomyositis, Rheumatic Diseases, Juvenile Idiopathic Arthritis (JIA), Familial Mediterranean Fever (FMF)
- Trial name
- NCT07138157
- Testing
- External Focus Exercises, Internal Focus Exercises
- Where
- Turkey (Türkiye)
- Volunteers
- 28 people
- Sponsor
- Istanbul University - Cerrahpasa
Juvenile Idiopathic Arthritis
Optimizing Treatment for Patients With Juvenile Idiopathic Arthritis in Sustained Remission: The MOVE-JIA Trial
The goal of this clinical trial is to compare three different maintenance and step-down treatment strategies in children and adolescents with juvenile idiopathic arthritis in sustained remission.
- Trial name
- MOVE-JIA (NCT06653634)
- Testing
- Methotrexate, TNF Inhibitor
- Where
- 7 sites in Norway
- Volunteers
- 150 people
- Sponsor
- Oslo University Hospital
Juvenile Idiopathic Arthritis
MSUS Versus Serum Survivin and Lubricin Levels in Evaluation of Disease Activity in JIA
Aim of the work The aim of this study is to compare the role of musculoskeletal ultrasound to serum Survivin and Lubricin in detection of disease activity in patients with oligoarticular and polyarticular juvenile idiopathic…
- Trial name
- NCT05545098
- Volunteers
- 106 people
- Sponsor
- Assiut University
Juvenile Idiopahtic Arthritis
30-Second Sit-to-Stand Test for Assessing Functional Capacity in Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis (JIA) is a heterogeneous, idiopathic, chronic inflammatory, rheumatic disease that is most common in childhood and is thought to involve immunological mechanisms in its etiopathogenesis.
- Trial name
- NCT06609837
- Where
- Turkey (Türkiye)
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Istanbul University - Cerrahpasa
Juvenile Idiopathic Arthritis
Open-Label Extension of the Dose Finding Study (DSC/08/2357/36) in Patients With Poly Juvenile Idiopathic Arthritis
Primary Objective of the study: the purpose of this extension study was to determine the safety of Givinostat in a long term treatment of patients who participated in DSC/08/2357/36 study with good results (clinical benefit at…
- Trial name
- NCT01557452
- Testing
- Givinostat
- Where
- Czechia
- Volunteers
- 1 people
- Sponsor
- Italfarmaco
Juvenile Idiopathic Arthritis
A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis
This 3-part study evaluated the efficacy and safety of tocilizumab in patients with active polyarticular-course juvenile idiopathic arthritis who have an inadequate response to, or were intolerant of methotrexate.
- Trial name
- NCT00988221
- Testing
- Tocilizumab
- Where
- 69 sites in United States, Argentina and 13 more
- Volunteers
- 188 people
- Sponsor
- Hoffmann-La Roche
Juvenile Idiopathic Arthritis Associated Uveitis
Biologic Therapy in Pediatric JIA Uveitis
Juvenile Idiopathic Arthritis (JIA) remains the most common systemic disorder associated with pediatric uveitis. Studies estimate that 28-67% of patients with JIA-associated uveitis develop ocular complications, with 12%…
- Trial name
- NCT05540743
- Testing
- biologic DMARDs
- Where
- Egypt
- Volunteers
- 250 people
- Sponsor
- Kasr El Aini Hospital
Juvenile Idiopathic Arthritis, Children
M3-JIA: Making Mindfulness Matter for Children With JIA
The investigator will evaluate the efficacy of M3©, an intervention for patients with JIA and their caregivers. Children with Juvenile arthritis and their parents will attend an 8 week online program called Making Mindfulness…
- Conditions
- Juvenile Idiopathic Arthritis, Children, Mental Health, Mental Well-being
- Trial name
- M3-JIA (NCT06376149)
- Testing
- M3 Intervention group, M3 Waitlist Group
- Where
- 3 sites in Canada
- Volunteers
- 74 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Juvenile Idiopathic Arthritis
Survey on the Expectations of Adolescents With Juvenile Idiopathic Arthritis (JIA) Regarding Knowledge and Communication With Health Care Professionals in the Field of Sexual Health, and Their Parents' Views on the Subject. (SNAPS-JIA)
Sexual health is a legitimate area to explore in the care of these patients, as it has such an impact on quality of life. However, addressing sexual health in a situation of chronic disease confronts the double societal taboo of…
- Trial name
- SNAPS-JIA (NCT04791189)
- Testing
- questionnaire
- Where
- 15 sites in France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Clermont-Ferrand
Still's Disease, Adult-Onset, Systemic Inflammation
Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, and Related Conditions
Background: Inflammatory conditions can cause symptoms like fevers, arthritis, and rash. Systemic juvenile idiopathic arthritis (sJIA) is one of these conditions. So is adult-onset Still s disease (AOSD).
- Conditions
- Still's Disease, Adult-Onset, Systemic Inflammation, Arthritis, Autoinflammatory Syndrome
- Trial name
- NCT03510442
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Juvenile Idiopathic Arthritis (JIA)
Development of a Multidimensional Prediction Model for the Course and Outcome of Early-Onset Juvenile Idiopathic Arthritis (JIA)
This is a prospective-retrospective, translational, no profit, multicentric, observational study. A cohort of at least 100 early-onset JIA patients attending the Unit of Rheumatology and Autoinflammatory Diseases, Department of…
- Trial name
- NCT07882667
- Where
- 2 sites in Italy
- Volunteers
- 130 people
- Sponsor
- Istituto Giannina Gaslini
Arthritis, Juvenile Idiopathic
Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis
This study will evaluate the effect of etanercept on the clinical benefit, safety, and physical functioning (ability to function in daily life) in children and adolescent subjects with 3 subtypes of childhood arthritis.
- Trial name
- CLIPPER (NCT00962741)
- Testing
- Etanercept
- Where
- 42 sites in Australia, Belgium and 17 more
- Volunteers
- 127 people
- Sponsor
- Pfizer
Juvenile Idiopathic Arthritis
An Extension Study to WA19977 in Patients With Active Polyarticular-Course Juvenile Idiopathic Arthritis
This long-term, interventional, open-label extension study will evaluate the safety and efficacy of RoActemra/Actemra (tocilizumab) in patients from Poland and Russia with polyarticular-course juvenile idiopathic arthritis who…
- Trial name
- NCT01575769
- Testing
- RoActemra/Actemra (tocilizumab)
- Where
- 11 sites in Poland, Russia
- Volunteers
- 41 people
- Sponsor
- Hoffmann-La Roche
Systemic Juvenile Idiopathic Arthritis
Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA
This was a phase III study designed to provide efficacy and safety data for canakinumab administered for at least 48 weeks as subcutaneous (s.c.) injection every 4 weeks (q4wk) in Japanese patients with Systemic Juvenile…
- Trial name
- NCT02396212
- Testing
- Canakinumab
- Where
- 7 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals